Allergy Therapeutics Plc (AGY)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013547)
◆英語タイトル:Allergy Therapeutics Plc (AGY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013547
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alternative of aluminium to develop aluminium-free immunotherapy vaccines. Allergy Therapeutics product portfolio includes Pollinex Grasses + Rye and Pollinex Trees vaccines. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, Slovakia, Czech Republic, the Netherlands and the UK. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Allergy Therapeutics Plc (AGY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Allergy Therapeutics Plc, Medical Devices Deals, 2011 to YTD 2017 10
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12
Allergy Therapeutics Enters Into Distribution Agreement With Lincoln Medical 13
Equity Offering 14
Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 14
Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 15
Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 17
Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 18
Allergy Therapeutics Completes Private Placement Of Shares For US$0.3 Million 20
Acquisition 22
Allergy Therapeutics Acquires Alerpharma 22
Allergy Therapeutics Plc – Key Competitors 23
Allergy Therapeutics Plc – Key Employees 24
Allergy Therapeutics Plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Financial Announcements 27
Sep 28, 2017: Allergy Therapeutics: Preliminary Results 27
Mar 29, 2017: Allergy Therapeutics: Interim Results for the six months ended 31 December 2016 33
Jan 19, 2017: Allergy Therapeutics Provides Trading Update 34
Sep 26, 2016: Allergy Therapeutics: Preliminary report for the year ended 30 June 2016 35
Mar 08, 2016: Allergy Therapeutics Interim Results for the six months ended 31 December 2015 36
Jan 03, 2016: Allergy Therapeutics Revenue Up In First Half, Full Year Seen In Line 39
Corporate Communications 40
Jun 06, 2017: Allergy Therapeutics: Directorate changes 40
Feb 08, 2017: Allergy Therapeutics: Directorate Change 41
Mar 17, 2016: Allergy Therapeutics Announces Board change 42
Clinical Trials 43
Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study 43
Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 44
Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204 45
May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis 46
Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study 47
Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 48
Other Significant Developments 49
Jul 13, 2016: Allergy Therapeutics: Trading Update 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Allergy Therapeutics Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Allergy Therapeutics Plc, Medical Devices Deals, 2011 to YTD 2017 10
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12
Allergy Therapeutics Enters Into Distribution Agreement With Lincoln Medical 13
Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 14
Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 15
Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 17
Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 18
Allergy Therapeutics Completes Private Placement Of Shares For US$0.3 Million 20
Allergy Therapeutics Acquires Alerpharma 22
Allergy Therapeutics Plc, Key Competitors 23
Allergy Therapeutics Plc, Key Employees 24
Allergy Therapeutics Plc, Subsidiaries 25

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Allergy Therapeutics Plc (AGY)-製薬・医療分野:企業M&A・提携分析(Allergy Therapeutics Plc (AGY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆